TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The drug will be manufactured at the group’s topical facility at Ahmedabad
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Subscribe To Our Newsletter & Stay Updated
